All Patients (n = 78) | Non-Tumor (n = 41) | Tumor (n = 37) | P-value | |
---|---|---|---|---|
Demographics | ||||
Age at diagnosis: median (range) | 56 (44.25–63.5) | 59 (51–65) | 53 (38–60) | 0.015994 |
Male: No. (%) | 39 (50) | 20 (48.78) | 19 (51.35) | |
Race: No. (%) | 0.046301 | |||
White, non-Hispanic | 74 (94.87) | 41 (100) | 33 (89.19) | |
Black/African American, non-Hispanic | 4 (5.13) | 0 (0) | 4 (10.81) | |
Clinical Data | ||||
Histology | 0.652495 | |||
Glioblastoma multiforme: No. (%) | 74(94.87) | 39(95.12) | 35(94.59) | |
Glioblastoma small cell variant: No. (%) | 1(1.28) | 1(2.44) | 0(0) | |
Glioblastoma with oligodendroglioma: No. (%) | 1(1.28) | 1(2.44) | 0(0) | |
Glioblastoma, small cell variant: No. (%) | 1(1.28) | 0(0) | 1(2.7) | |
High grade glioneuronal tumor: No. (%) | 1(1.28) | 0(0) | 1(2.7) | |
Extent of surgical resection (N = 77) | 0.040166 | |||
biopsy | 5(6.49) | 0(0) | 5(13.51) | |
GTR | 55(71.43) | 32(80) | 23(62.16) | |
subtotal | 17(22.08) | 8(20) | 9(24.32) | |
MGMT Methylation Status (N = 70) | 1 | |||
Methylated: No. (%) | 21(30) | 11(28.95) | 10(31.25) | |
Unmethylated: No. (%) | 49(70) | 27(71.05) | 22(68.75) | |
KPS | 85(80 ~ 90) | 90(80 ~ 90) | 80(70 ~ 90) | 0.100858 |
Prior RT | 0.046301 | |||
No | 74(94.87) | 41(100) | 33(89.19) | |
Yes | 4(5.13) | 0(0) | 4(10.81) | |
Prior chemo | 0.221778 | |||
No | 76(97.44) | 41(100) | 35(94.59) | |
Yes | 2(2.56) | 0(0) | 2(5.41) | |
Prior immune suppression tx | 1 | |||
No | 76(97.44) | 40(97.56) | 36(97.3) | |
Yes | 2(2.56) | 1(2.44) | 1(2.7) | |
Baseline steriod use (N = 76) | 1 | |||
No | 38(50) | 21(51.22) | 17(48.57) | |
Yes | 38(50) | 20(48.78) | 18(51.43) | |
Treatment regimen | 0.494838 | |||
Concurrent RT/TMZ | 76(97.44) | 39(95.12) | 37(100) | |
RTonly | 2(2.56) | 2(4.88) | 0(0) | |
Adjuvant Chemo | 1 | |||
No | 1(1.28) | 1(2.44) | 0(0) | |
Yes | 77(98.72) | 40(97.56) | 37(100) | |
Infection | 0.702159 | |||
No | 71(91.03) | 38(92.68) | 33(89.19) | |
Yes | 7(8.97) | 3(7.32) | 4(10.81) | |
Pathology at 2nd Surgery | 0.000000 | |||
mixed | 29(37.18) | 29(70.73) | 0(0) | |
necrosis/tx effect | 12(15.38) | 12(29.27) | 0(0) | |
tumor | 37(47.44) | 0(0) | 37(100) | |
Laboratory Data | ||||
ALC_beforeRT (N = 75): median (range) | 1.4 (0.9–1.9) | 1.2 (0.9–1.9) | 1.4 (0.9–2.3) | 0.303656 |
ALC_postRT (N = 73): median (range) | 0.9 (0.6–1.3) | 1 (0.6–1.3) | 0.9 (0.68–1.23) | 0.742197 |
ALC_MRIProgression (N = 74): median | 1 (0.7–1.5) | 1 (0.72–1.5) | 0.95 (0.7–1.62) | 0.777925 |
Baseline CD4 counts (N = 14): median (range) | 908 (619–1070.5) | 1054 (888.25–1172.5) | 763.5 (593.25–950) | 0.217997 |
POST RT/Chemo CD4 count (N = 23): median (range) | 344 (269.5–490.5) | 404.5 (276.75–530.25) | 344 (263–345) | 0.377232 |
CD4 count_MRIProgression (N = 15): median (range) | 340 (253–532) | 484.5 (321–705.25) | 253 (175–299.5) | 0.048736 |